Patrys Limited is a publicly-listed company based in Sparta, NJ, that specializes in developing innovative antibody technologies for the treatment of challenging cancers. Their revolutionary deoxymab platform utilizes unique and proprietary antibodies that have the ability to seek out cancer cells throughout the body, penetrate cells and the cell nucleus, and cross the blood-brain barrier. By inhibiting DNA damage repair, Patrys aims to provide effective therapies for various cancers, either as single agent treatments for cancers with existing DNA damage repair deficiencies or in combination with chemotherapy or radiation therapies.
With a focus on delivering therapeutic payloads into the cell nucleus, Patrys is at the forefront of developing groundbreaking approaches to combat cancer. Their cutting-edge antibody technologies hold great promise in revolutionizing cancer treatment and improving patient outcomes.
Generated from the website